Skip the chemo: Millions of breast cancer patients could be spared chemotherapy with groundbreaking genomic test
A groundbreaking international trial, Optima, reveals a genomic test, Prosigna, can identify breast cancer patients unlikely to benefit from chemotherapy. This precision oncology approach analyzes tumor genes, potentially sparing thousands of women the harsh side effects of chemo while maintaining similar survival rates. The findings promise a more personalized and less burdensome cancer treatment future.
A groundbreaking international trial, Optima, reveals a genomic test, Prosigna, can identify breast cancer patients unlikely to benefit from chemotherapy. This precision oncology approach analyzes tumor genes, potentially sparing thousands of women the harsh side effects of chemo while maintaining similar survival rates. The findings promise a more personalized and less burdensome cancer treatment future.
